201 related articles for article (PubMed ID: 32249812)
1. Network-based metabolic characterization of renal cell carcinoma.
Pandey N; Lanke V; Vinod PK
Sci Rep; 2020 Apr; 10(1):5955. PubMed ID: 32249812
[TBL] [Abstract][Full Text] [Related]
2. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
3. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
Ricketts CJ; De Cubas AA; Fan H; Smith CC; Lang M; Reznik E; Bowlby R; Gibb EA; Akbani R; Beroukhim R; Bottaro DP; Choueiri TK; Gibbs RA; Godwin AK; Haake S; Hakimi AA; Henske EP; Hsieh JJ; Ho TH; Kanchi RS; Krishnan B; Kwiatkowski DJ; Liu W; Merino MJ; Mills GB; Myers J; Nickerson ML; Reuter VE; Schmidt LS; Shelley CS; Shen H; Shuch B; Signoretti S; Srinivasan R; Tamboli P; Thomas G; Vincent BG; Vocke CD; Wheeler DA; Yang L; Kim WY; Robertson AG; ; Spellman PT; Rathmell WK; Linehan WM
Cell Rep; 2018 Apr; 23(1):313-326.e5. PubMed ID: 29617669
[TBL] [Abstract][Full Text] [Related]
4. Glutathione Metabolism in Renal Cell Carcinoma Progression and Implications for Therapies.
Xiao Y; Meierhofer D
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357507
[TBL] [Abstract][Full Text] [Related]
5. Changes in levels of metabolic pathway gene expression under conditions of clear cell renal carcinoma.
Bashmakov VY; Gorbacheva TM; Panevina AV; Solodskikh SA; Moshurov IP; Mikhaylov AA; Maslov AY; Popov VN
Dokl Biochem Biophys; 2017 May; 474(1):159-161. PubMed ID: 28726105
[TBL] [Abstract][Full Text] [Related]
6. Metabolic reprogramming in renal cancer: Events of a metabolic disease.
Chakraborty S; Balan M; Sabarwal A; Choueiri TK; Pal S
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188559. PubMed ID: 33965513
[TBL] [Abstract][Full Text] [Related]
7. PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth.
Abu Aboud O; Donohoe D; Bultman S; Fitch M; Riiff T; Hellerstein M; Weiss RH
Am J Physiol Cell Physiol; 2015 Jun; 308(11):C890-8. PubMed ID: 25810260
[TBL] [Abstract][Full Text] [Related]
8. Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism.
Leisz S; Schulz K; Erb S; Oefner P; Dettmer K; Mougiakakos D; Wang E; Marincola FM; Stehle F; Seliger B
Oncotarget; 2015 May; 6(13):11395-406. PubMed ID: 25890500
[TBL] [Abstract][Full Text] [Related]
9. Metabolomics informs common patterns of molecular dysfunction across histologies of renal cell carcinoma.
DiNatale RG; Sanchez A; Hakimi AA; Reznik E
Urol Oncol; 2020 Oct; 38(10):755-762. PubMed ID: 31155438
[TBL] [Abstract][Full Text] [Related]
10. Messenger RNA expression ratios among four genes predict subtypes of renal cell carcinoma and distinguish oncocytoma from carcinoma.
Chen YT; Tu JJ; Kao J; Zhou XK; Mazumdar M
Clin Cancer Res; 2005 Sep; 11(18):6558-66. PubMed ID: 16166433
[TBL] [Abstract][Full Text] [Related]
11. Integrated genomic analysis identifies clinically relevant subtypes of renal clear cell carcinoma.
Wu P; Liu JL; Pei SM; Wu CP; Yang K; Wang SP; Wu S
BMC Cancer; 2018 Mar; 18(1):287. PubMed ID: 29534679
[TBL] [Abstract][Full Text] [Related]
12. LC-MS based metabolomic profiling for renal cell carcinoma histologic subtypes.
Jing L; Guigonis JM; Borchiellini D; Durand M; Pourcher T; Ambrosetti D
Sci Rep; 2019 Oct; 9(1):15635. PubMed ID: 31666664
[TBL] [Abstract][Full Text] [Related]
13. Cell-Type-Specific Gene Programs of the Normal Human Nephron Define Kidney Cancer Subtypes.
Lindgren D; Eriksson P; Krawczyk K; Nilsson H; Hansson J; Veerla S; Sjölund J; Höglund M; Johansson ME; Axelson H
Cell Rep; 2017 Aug; 20(6):1476-1489. PubMed ID: 28793269
[TBL] [Abstract][Full Text] [Related]
14. Integrated transcriptomic and metabolomic analysis shows that disturbances in metabolism of tumor cells contribute to poor survival of RCC patients.
Popławski P; Tohge T; Bogusławska J; Rybicka B; Tański Z; Treviño V; Fernie AR; Piekiełko-Witkowska A
Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):744-752. PubMed ID: 28012969
[TBL] [Abstract][Full Text] [Related]
15. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers.
Takahashi M; Yang XJ; Sugimura J; Backdahl J; Tretiakova M; Qian CN; Gray SG; Knapp R; Anema J; Kahnoski R; Nicol D; Vogelzang NJ; Furge KA; Kanayama H; Kagawa S; Teh BT
Oncogene; 2003 Oct; 22(43):6810-8. PubMed ID: 14555994
[TBL] [Abstract][Full Text] [Related]
16. Identification of the key genes and pathways involved in the tumorigenesis and prognosis of kidney renal clear cell carcinoma.
Cui H; Shan H; Miao MZ; Jiang Z; Meng Y; Chen R; Zhang L; Liu Y
Sci Rep; 2020 Mar; 10(1):4271. PubMed ID: 32144299
[TBL] [Abstract][Full Text] [Related]
17. A Differential Transcriptional Regulome Approach to Unpack Cancer Biology: Insights on Renal Cell Carcinoma Subtypes.
Caliskan A; Arga KY
OMICS; 2023 Nov; 27(11):536-545. PubMed ID: 37943533
[TBL] [Abstract][Full Text] [Related]
18. Proteotranscriptomic Analysis Reveals Stage Specific Changes in the Molecular Landscape of Clear-Cell Renal Cell Carcinoma.
Neely BA; Wilkins CE; Marlow LA; Malyarenko D; Kim Y; Ignatchenko A; Sasinowska H; Sasinowski M; Nyalwidhe JO; Kislinger T; Copland JA; Drake RR
PLoS One; 2016; 11(4):e0154074. PubMed ID: 27128972
[TBL] [Abstract][Full Text] [Related]
19. Integrative analysis of protein-coding and non-coding RNAs identifies clinically relevant subtypes of clear cell renal cell carcinoma.
Li Z; Chen Y; Hu S; Zhang J; Wu J; Ren W; Shao N; Ying X
Oncotarget; 2016 Dec; 7(50):82671-82685. PubMed ID: 27705920
[TBL] [Abstract][Full Text] [Related]
20. Endocytosis-Mediated Replenishment of Amino Acids Favors Cancer Cell Proliferation and Survival in Chromophobe Renal Cell Carcinoma.
Xiao Y; Rabien A; Buschow R; Amtislavskiy V; Busch J; Kilic E; Villegas SL; Timmermann B; Schütte M; Mielke T; Yaspo ML; Jung K; Meierhofer D
Cancer Res; 2020 Dec; 80(24):5491-5501. PubMed ID: 33115803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
